AZTherapies to Present at the 25th Annual BIO-EUROPE® International Partnering Conference
The presentation will highlight AZTherapies lead Phase 3 clinical candidate ALZT-OP1 for the treatment of early Alzheimers disease and its pipeline of candidates targeting neuroinflammation to treat neurodegenerative diseases.
BOSTON, Nov. 04, 2019 (GLOBE NEWSWIRE) -- AZTherapies, Inc., a biopharmaceutical company developing therapeutics to extend brain health, today announced that its Director of Business Development, Parid Sava, Ph.D., will be presenting at BIO-EUROPE’s 25th Annual International Partnering Conference, taking place from November 11 to 13, 2019 in Hamburg, Germany. The presentation will highlight AZTherapies’ lead Phase 3 clinical candidate ALZT-OP1 for the treatment of early Alzheimer’s disease and its pipeline of candidates targeting neuroinflammation to treat neurodegenerative diseases.
When: Monday, November 11, 2019 at 4:00 pm
Where: Level 1, Hall B1, Room 6
About BIO-EUROPE
Now celebrating its 25th year, BIO-EUROPE is Europe’s largest life science partnering conference. Bringing together international decision makers from the biotechnology, pharmaceutical, and financial sectors, the conference offers networking opportunities, workshop and panel participation, high-profile exhibitions, and prearranged one-to-one meetings. BIO-EUROPE is produced by EBD Group, a leading partnering firm for the global biotechnology industry, with the support of the Biotechnology Innovation Organization (BIO).
About AZTherapies
AZTherapies is an advanced clinical-stage biopharmaceutical company developing novel therapies that aim to fundamentally change neurodegenerative disease progression, extending normal cognition and function and improving quality of life in the aging population. Advancing a growing pipeline of candidates to treat patients with few therapeutic options, our lead candidate, ALZT-OP1, is built on a multi-modal approach that recognizes neuroinflammation as a root cause of serious neurodegeneration and seeks to stop or slow the progression of disease. Our Phase 3 COGNITE trial in early Alzheimer’s disease is fully enrolled and expected to complete in late 2020. Following our lead program, we are advancing candidates for the treatment of post-ischemic stroke cognitive impairment, amyotrophic lateral sclerosis (ALS), and other indications. AZTherapies is a private company headquartered in Boston, Massachusetts. To learn more, please visit www.aztherapies.com.
Media Contact:
Jennifer LaVin
207-360-0473
[email protected]
Investor Contact:
Courtney Turiano
212-698-8687
[email protected]
